Advertisment

Cellworks, Lifeline Hospitals collaborate for oncology

author-image
CIOL Bureau
Updated On
New Update

BANGALORE, INDIA: Cellworks Research India Ltd, the R&D wing of California based company Cellworks Group Inc and Lifeline Multi Speciality Hospitals have announced a one-year research collaboration in the area of oncology with emphasis on study of the role of tumor stem cells in cancer pathology and progression. This collaborative research will elucidate novel biochemical markers to identify disease progression and patient sub-types enabling solutions for personalized medicine. This research project will be based on Cellworks proprietary iC-PHYS Tumor Cell platform which is Multi Drug Resistance (MDR) Aware technology.

Advertisment

This collaborative research will exploit the unique prowess of Cellworks technology iC-PHYS, a proprietary in silico platform, which provides a disease physiology aligned dynamic representation at the bio-molecular abstraction level. The technology platform iC-PHYS Tumor Cell, is MDR Aware and enables virtual prototyping to incorporate drug-resistance factors in the drug discovery process. This prototyping minimizes efficacy issues due to drug resistance that may show up at clinical trials stages. Also the various cancer phenotypes are comprehensively included in this technology platform.

According to Dr. J.S. Rajkumar – Founder and Chairman, Lifeline Hospitals: “Lifeline Hospitals is pioneering Clinical Trials using cell-based therapies. One significant need for us to offer differentiated solutions in the area of oncology is to gain deep knowledge of the sequential cellular level events which take place during cancer progression. We are partnering with Cellworks Group Inc. to better understand the details of the cellular bio-chemical pathways and proteins involved in the differentiation process. Cellworks team with its in-depth expertise in cellular modeling and rich library of in silico based proprietary platforms has been identified to be the optimal partner in this exciting and emergent area. Lifeline is proud to be associated with a pioneering company like Cellworks.”

“I am very excited with the potential of this partnership,” said Taher Abbasi, CEO of Cellworks. “Molecular bio-markers identification is fundamental for understanding cancer progression and for adaptive treatment solutions for maximum efficacy and minimized drug resistance. Transparency into all cancer phenotypes and intermediate nodes simultaneously through the iC-PHYS platform and correlation with the clinical data points will expand opportunities for personalized medicine in cancer treatment."

Dr. Anand Kumar, Chairman Board of Cellworks Research India Ltd, added: "It gives me great pleasure to see two best in class companies coming together through this engagement model. It is very exciting to observe the extensibility of the Cellworks’ solutions to a very new facet of oncology research."

semicon